Posted by Michael Wonder on 01 Sep 2020
Update on the agenda for the November 2020 PBAC meeting
1 September 2020 - Less than one week in and the agenda for the next scheduled PBAC meeting has already been changed.
Two changes have been made; one minor (Zolgensma) and the other major (Rinvoq). The PBAC has been asked by AbbVie to review the statistical basis upon which the claim of superior effectiveness of upadacitinib monohydrate versus adalimumab for the treatment of patients with severe active rheumatoid arthritis was not accepted. One to watch closely.
The URL remains unchanged and the website states the agenda webpage has not been updated since 26 August 2020. Not a great example of the Government setting a good example on improved transparency.
